Assessment of the protection afforded by triple baculovirus recombinant coexpressing H5, N3, M1 proteins against a homologous H5N3 low-pathogenicity avian influenza virus challenge in Muscovy ducks.
In Asia, domestic ducks have been shown to play a pivotal role in H5 high-pathogenicity avian influenza virus transmission. We have also observed that the same situation may exist for H5 low-pathogenicity avian influenza (LPAI) virus. No data are available regarding the protection afforded by commercial inactivated vaccines against H5 LPAI virus infection in ducks, and two preliminary experiments using commercial inactivated vaccines gave poor results. Virus-like particles (VLPs) have been shown to be immunogenic in different species. With regard to the influenza model, the matrix (M) protein has been shown to be necessary for the formation of VLPs. In order to attempt to develop a VLP influenza vaccine expressing hemagglutinin and neuraminidase (NA) of interest, we generated a triple recombinant baculovirus (rB) expressing three structural proteins: H5, N3, and M, derived from a recent French LPAI virus strain. Although the three proteins were successfully expressed in rB-infected cells and displayed the expected biological activity, no VLPs were observed. Despite this result, the protection afforded to ducks by rB-infected cell lysates was assessed and was compared with the protection afforded by an inactivated commercial H5N9 vaccine. For this purpose, specific-pathogen-free Muscovy ducks (15 per group) received rB-infected cell lysates (3 wk apart), while a second group received the H5N9 vaccine. Ten days after the boost, a homologous virus challenge was implemented. Both vaccines induced positive hemagglutination inhibition titers and M immune response, whereas lysates of rB-infected cells elicited NA immune response. Tracheal and cloacal sheddings were measured using M-based real-time-reverse transcription-polymerase chain reaction and were compared with the sheddings of vaccinated and unvaccinated infected controls. Lysates of rB-infected cells afforded a significant decrease of cloacal shedding and a delayed peak of tracheal shedding, whereas the inactivated commercial vaccine afforded a significant decrease of tracheal shedding only.
Prel
Anne
A
AFSSA, Swine and Poultry Research Laboratory, French National Reference Laboratory for Avian Influenza and Newcastle Disease, Avian and Rabbit Virology, Immunology and Parasitology Unit, B.P. 53, 22440 Ploufragan, France.
Le Gall-Reculé
Ghislaine
G
Cherbonnel
Martine
M
Grasland
Béatrice
B
Amelot
Michel
M
Jestin
Véronique
V
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D016367:Baculoviridae; D004372:Ducks; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology* / Q000378:metabolism; D009980:Influenza A virus / Q000145:classification* / Q000472:pathogenicity; D007252:Influenza Vaccines / Q000276:immunology*; D005585:Influenza in Birds / Q000517:prevention & control; D011994:Recombinant Proteins; D013047:Specific Pathogen-Free Organisms; D014763:Viral Matrix Proteins / Q000276:immunology* / Q000378:metabolism; D017361:Viral Nonstructural Proteins / Q000276:immunology* / Q000378:metabolism
D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; C488936:M1 protein, Influenza A virus; D011994:Recombinant Proteins; D014763:Viral Matrix Proteins; D017361:Viral Nonstructural Proteins; C109963:hemagglutinin, avian influenza A virus